These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 27785772)

  • 1. A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies.
    Wei CY; Quek RGW; Villa G; Gandra SR; Forbes CA; Ryder S; Armstrong N; Deshpande S; Duffy S; Kleijnen J; Lindgren P
    Pharmacoeconomics; 2017 Mar; 35(3):297-318. PubMed ID: 27785772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.
    Ara R; Pandor A; Stevens J; Rees A; Rafia R
    Health Technol Assess; 2009 Jul; 13(34):1-74, 75-118. PubMed ID: 19604457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis.
    Vegter S; Oosterhof P; van Boven JF; Stuurman-Bieze AG; Hiddink EG; Postma MJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):722-32. PubMed ID: 24967525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
    Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ
    Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of cost-effectiveness analyses of lipid-lowering therapies: From the policy-maker's desk to the patient's bedside.
    Kazi DS; Virani SS
    Prog Cardiovasc Dis; 2019; 62(5):406-413. PubMed ID: 31672610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study.
    Shepherd J
    Am J Cardiol; 2001 Mar; 87(5A):19B-22B. PubMed ID: 11256845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic literature review of methods of incorporating mortality in cost-effectiveness analyses of lipid-lowering therapies.
    Ortendahl JD; Harmon AL; Bentley TGK; Broder MS
    J Med Econ; 2017 Jul; 20(7):767-775. PubMed ID: 28562126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
    Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
    Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
    Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
    Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
    Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review.
    Ashfaq K; Yahaya I; Hyde C; Andronis L; Barton P; Bayliss S; Chen YF
    Health Technol Assess; 2010 Dec; 14(54):iii-iv, ix-xi, 1-141. PubMed ID: 21138675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severely frail elderly patients do not need lipid-lowering drugs.
    Mallery LH; Moorhouse P; McLean Veysey P; Allen M; Fleming I
    Cleve Clin J Med; 2017 Feb; 84(2):131-142. PubMed ID: 28198686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Carroll C; Tappenden P; Rafia R; Hamilton J; Chambers D; Clowes M; Durrington P; Qureshi N; Wierzbicki AS
    Pharmacoeconomics; 2017 May; 35(5):537-547. PubMed ID: 28285379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperlipidemia: Drugs for Cardiovascular Risk Reduction in Adults.
    Last AR; Ference JD; Menzel ER
    Am Fam Physician; 2017 Jan; 95(2):78-87. PubMed ID: 28084704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications.
    Chapman RH; Kowal SL; Cherry SB; Ferrufino CP; Roberts CS; Chen L
    Value Health; 2010; 13(6):685-94. PubMed ID: 20825627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
    Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
    Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.